Weight-loss drugs fail long-term as patients regain pounds after stopping treatment

New research highlights the challenges of keeping weight off after stopping popular weight-loss drugs. Patients who end treatment regain lost weight much faster than those who lose it through diet and exercise alone. The findings also reveal that additional health benefits, like improved cholesterol and blood pressure, disappear once medication stops.

A recent study found that people on drugs like Ozempic, Wegovy, and Mounjaro regain weight in around 1.5 years—sooner than the two years previously assumed. Earlier cost-effectiveness models for these treatments had overestimated their long-term impact. The issue reflects a broader problem: obesity is a chronic condition, and stopping treatment often leads to rapid weight regain.

About half of patients quit these medications within a year due to side effects, high costs, or dissatisfaction with results. In the U.K., 90% of users pay privately, while NHS patients face a two-year limit on GLP-1 drug access. Even when prescribed, these drugs are rarely covered by health insurance unless the patient has diabetes or other complications. Current obesity treatments combine lifestyle changes, medication, and surgery. The first step is usually six months of nutrition counselling, exercise, and psychological support. Surgery is only considered after this baseline therapy, but funding remains a barrier. Experts argue that better access to long-term treatments is needed, as obesity often requires ongoing management rather than short-term fixes.

The study confirms that weight-loss drugs provide significant benefits only while in use. Once stopped, patients regain weight quickly and lose health improvements. Without better insurance coverage and long-term treatment options, managing obesity effectively remains difficult for many.